Taking this into account and considering that oncobiome composition indicates dysbiosis, and it is known that dysbiosis can influence the oncogenic process and, therefore, disease progression, as well as affect the efficacy of antineoplastic therapies (11), we suggest that dysbiosis may vary according to tumor size, patients’ breastfeeding history, and hormonal receptor status. Here, NR4A1 is linked to neoplasm.